Share Price and Basic Stock Data
Last Updated: January 6, 2026, 7:28 pm
| PEG Ratio | 4.15 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Max Healthcare Institute Ltd operates in the Hospitals & Medical Services sector and reported a price of ₹1,052 with a market capitalization of ₹1,02,370 Cr. The company has shown robust revenue growth over the years, with sales rising from ₹1,608 Cr in March 2017 to ₹4,563 Cr in March 2023. For the trailing twelve months (TTM), revenues reached ₹7,941 Cr, reflecting a significant increase in operational scale. Quarterly sales have also demonstrated a consistent upward trend, with ₹1,363 Cr reported in September 2023, rising to ₹1,423 Cr by March 2024. The operating profit margin (OPM) stood at 27% for the most recent fiscal year, indicating strong operational efficiency. The company’s business model appears resilient, supported by a diverse service offering in healthcare, which is crucial for sustaining growth in an evolving industry.
Profitability and Efficiency Metrics
Max Healthcare’s profitability metrics exhibit a healthy trend, with the net profit recorded at ₹1,357 Cr and a return on equity (ROE) of 12.7%. The operating profit showed an increase to ₹1,849 Cr for the fiscal year ending March 2025, with an OPM of 26%. The company’s interest coverage ratio (ICR) is notably high at 12.15x, suggesting strong capacity to meet interest obligations. The cash conversion cycle (CCC) was recorded at -138 days, indicating efficient management of working capital, allowing the company to convert its investments in inventory and receivables into cash quickly. However, the recent quarterly fluctuation in net profit—from ₹291 Cr in December 2023 to ₹252 Cr in March 2024—highlights potential volatility in earnings that could affect investor sentiment.
Balance Sheet Strength and Financial Ratios
Max Healthcare’s balance sheet reflects substantial strength, with total assets amounting to ₹15,186 Cr as of March 2025. The company reported reserves of ₹9,080 Cr against borrowings of ₹3,275 Cr, resulting in a healthy debt-to-equity ratio of 0.26. This low leverage indicates a conservative approach to capital structure, which can be advantageous in times of economic uncertainty. The price-to-book value (P/BV) ratio stood at 11.37x, suggesting that the market values the company significantly higher than its book value, indicative of favorable market sentiment. Furthermore, the return on capital employed (ROCE) is reported at 15%, demonstrating effective utilization of capital to generate profits. These metrics collectively present a robust financial position, conducive for future growth and strategic investments.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Max Healthcare demonstrates a diversified investor base, with Foreign Institutional Investors (FIIs) holding 51.80%, Domestic Institutional Investors (DIIs) at 20.03%, and promoters retaining 23.74% of shares. This distribution indicates strong institutional confidence in the company’s prospects, which is beneficial for liquidity and stability. The number of shareholders has increased significantly to 1,80,891 by September 2025, reflecting growing interest among retail investors. However, the decline in promoter holding from 23.78% in December 2022 to 23.74% in September 2025 may raise concerns about insider confidence. Investor sentiment may also be influenced by fluctuations in the stock price, particularly given the high P/E ratio of 72.6, which suggests that the stock is priced for substantial growth expectations.
Outlook, Risks, and Final Insight
Looking ahead, Max Healthcare is well-positioned to capitalize on the growing healthcare market in India, driven by increasing demand for quality medical services. However, the company faces risks such as potential regulatory changes and competition in the healthcare sector, which could impact margins and operational performance. Additionally, the variability in quarterly earnings highlights the importance of maintaining consistent revenue streams. If the company can sustain its growth trajectory and manage its costs effectively, it stands to enhance shareholder value significantly. Conversely, any adverse developments in healthcare policy or economic conditions may pose challenges. Overall, Max Healthcare’s strong fundamentals and strategic positioning provide a solid foundation for future growth while necessitating vigilant risk management practices.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 51.3 Cr. | 153 | 187/120 | 10.5 | 117 | 2.29 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.3 Cr. | 22.2 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 9.18 Cr. | 8.87 | 20.8/7.08 | 102 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 110 Cr. | 58.9 | 98.7/55.2 | 24.4 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.5 Cr. | 3.79 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,817.71 Cr | 712.78 | 92.93 | 93.18 | 0.32% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,137 | 1,142 | 1,215 | 1,285 | 1,363 | 1,335 | 1,423 | 1,543 | 1,707 | 1,868 | 1,910 | 2,028 | 2,135 |
| Expenses | 818 | 828 | 874 | 948 | 976 | 949 | 1,041 | 1,156 | 1,257 | 1,369 | 1,398 | 1,505 | 1,560 |
| Operating Profit | 319 | 314 | 340 | 337 | 387 | 386 | 382 | 387 | 451 | 499 | 512 | 523 | 575 |
| OPM % | 28% | 28% | 28% | 26% | 28% | 29% | 27% | 25% | 26% | 27% | 27% | 26% | 27% |
| Other Income | 26 | 45 | 40 | 41 | 45 | 46 | 45 | 35 | 41 | -40 | 47 | 37 | 33 |
| Interest | 22 | 20 | 20 | 19 | 9 | 11 | 21 | 24 | 34 | 52 | 55 | 55 | 54 |
| Depreciation | 58 | 57 | 60 | 56 | 58 | 61 | 70 | 77 | 84 | 98 | 101 | 104 | 108 |
| Profit before tax | 265 | 281 | 301 | 303 | 366 | 360 | 336 | 321 | 374 | 309 | 402 | 400 | 446 |
| Tax % | -72% | 21% | 17% | 21% | 24% | 20% | 25% | 26% | 25% | 23% | 21% | 23% | -10% |
| Net Profit | 457 | 222 | 251 | 240 | 277 | 289 | 252 | 236 | 282 | 239 | 319 | 308 | 491 |
| EPS in Rs | 4.72 | 2.29 | 2.58 | 2.47 | 2.85 | 2.98 | 2.59 | 2.43 | 2.90 | 2.46 | 3.28 | 3.17 | 5.05 |
Last Updated: December 30, 2025, 12:36 am
Below is a detailed analysis of the quarterly data for Max Healthcare Institute Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,028.00 Cr. (Jun 2025) to 2,135.00 Cr., marking an increase of 107.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,560.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,505.00 Cr. (Jun 2025) to 1,560.00 Cr., marking an increase of 55.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 575.00 Cr.. The value appears strong and on an upward trend. It has increased from 523.00 Cr. (Jun 2025) to 575.00 Cr., marking an increase of 52.00 Cr..
- For OPM %, as of Sep 2025, the value is 27.00%. The value appears strong and on an upward trend. It has increased from 26.00% (Jun 2025) to 27.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Jun 2025) to 33.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Sep 2025, the value is 54.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 55.00 Cr. (Jun 2025) to 54.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 104.00 Cr. (Jun 2025) to 108.00 Cr., marking an increase of 4.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 446.00 Cr.. The value appears strong and on an upward trend. It has increased from 400.00 Cr. (Jun 2025) to 446.00 Cr., marking an increase of 46.00 Cr..
- For Tax %, as of Sep 2025, the value is -10.00%. The value appears to be improving (decreasing) as expected. It has decreased from 23.00% (Jun 2025) to -10.00%, marking a decrease of 33.00%.
- For Net Profit, as of Sep 2025, the value is 491.00 Cr.. The value appears strong and on an upward trend. It has increased from 308.00 Cr. (Jun 2025) to 491.00 Cr., marking an increase of 183.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 5.05. The value appears strong and on an upward trend. It has increased from 3.17 (Jun 2025) to 5.05, marking an increase of 1.88.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:59 am
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,608 | 1,729 | 1,691 | 1,059 | 2,505 | 3,931 | 4,563 | 5,406 | 7,028 | 7,941 |
| Expenses | 1,467 | 1,616 | 1,535 | 965 | 2,101 | 2,986 | 3,322 | 3,914 | 5,180 | 5,832 |
| Operating Profit | 141 | 113 | 156 | 94 | 404 | 946 | 1,241 | 1,492 | 1,849 | 2,109 |
| OPM % | 9% | 7% | 9% | 9% | 16% | 24% | 27% | 28% | 26% | 27% |
| Other Income | 59 | 65 | 56 | 48 | -119 | 115 | 139 | 178 | 82 | 76 |
| Interest | 100 | 99 | 101 | 83 | 179 | 101 | 84 | 60 | 165 | 216 |
| Depreciation | 96 | 94 | 103 | 46 | 174 | 221 | 232 | 245 | 359 | 411 |
| Profit before tax | 5 | -15 | 8 | 13 | -69 | 739 | 1,064 | 1,365 | 1,406 | 1,558 |
| Tax % | -236% | 65% | 102% | -1% | 67% | 18% | -4% | 23% | 24% | |
| Net Profit | 16 | -25 | -0 | 59 | -138 | 605 | 1,104 | 1,058 | 1,076 | 1,357 |
| EPS in Rs | 0.29 | -0.47 | -0.06 | 1.10 | -1.42 | 6.24 | 11.37 | 10.88 | 11.07 | 13.96 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 9% | 14% | 14% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -256.25% | 100.00% | -333.90% | 538.41% | 82.48% | -4.17% | 1.70% |
| Change in YoY Net Profit Growth (%) | 0.00% | 356.25% | -433.90% | 872.30% | -455.93% | -86.65% | 5.87% |
Max Healthcare Institute Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 21% |
| TTM: | 33% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 64% |
| 3 Years: | 23% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 59% |
| 3 Years: | 45% |
| 1 Year: | 32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 14% |
| Last Year: | 13% |
Last Updated: Unknown
Balance Sheet
Last Updated: December 10, 2025, 3:04 am
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 537 | 537 | 537 | 537 | 966 | 970 | 971 | 972 | 972 | 972 |
| Reserves | 655 | 627 | 426 | 2,016 | 4,673 | 5,313 | 6,439 | 7,436 | 8,409 | 9,080 |
| Borrowings | 874 | 981 | 1,003 | 875 | 1,101 | 913 | 689 | 1,299 | 3,010 | 3,275 |
| Other Liabilities | 1,080 | 1,157 | 1,389 | 546 | 1,803 | 1,993 | 2,003 | 2,293 | 2,795 | 2,954 |
| Total Liabilities | 3,146 | 3,302 | 3,355 | 3,974 | 8,543 | 9,189 | 10,102 | 12,000 | 15,186 | 16,281 |
| Fixed Assets | 2,244 | 2,227 | 2,192 | 851 | 6,536 | 7,018 | 7,039 | 8,784 | 11,502 | 11,826 |
| CWIP | 46 | 38 | 87 | 28 | 27 | 151 | 252 | 553 | 901 | 1,226 |
| Investments | 0 | 0 | 1 | 2,182 | 1 | 1 | 1 | 2 | 3 | 5 |
| Other Assets | 856 | 1,036 | 1,075 | 913 | 1,980 | 2,020 | 2,810 | 2,661 | 2,781 | 3,223 |
| Total Assets | 3,146 | 3,302 | 3,355 | 3,974 | 8,543 | 9,189 | 10,102 | 12,000 | 15,186 | 16,281 |
Below is a detailed analysis of the balance sheet data for Max Healthcare Institute Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 972.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 972.00 Cr..
- For Reserves, as of Sep 2025, the value is 9,080.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,409.00 Cr. (Mar 2025) to 9,080.00 Cr., marking an increase of 671.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,275.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3,010.00 Cr. (Mar 2025) to 3,275.00 Cr., marking an increase of 265.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,954.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,795.00 Cr. (Mar 2025) to 2,954.00 Cr., marking an increase of 159.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 16,281.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15,186.00 Cr. (Mar 2025) to 16,281.00 Cr., marking an increase of 1,095.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11,826.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,502.00 Cr. (Mar 2025) to 11,826.00 Cr., marking an increase of 324.00 Cr..
- For CWIP, as of Sep 2025, the value is 1,226.00 Cr.. The value appears strong and on an upward trend. It has increased from 901.00 Cr. (Mar 2025) to 1,226.00 Cr., marking an increase of 325.00 Cr..
- For Investments, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,223.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,781.00 Cr. (Mar 2025) to 3,223.00 Cr., marking an increase of 442.00 Cr..
- For Total Assets, as of Sep 2025, the value is 16,281.00 Cr.. The value appears strong and on an upward trend. It has increased from 15,186.00 Cr. (Mar 2025) to 16,281.00 Cr., marking an increase of 1,095.00 Cr..
Notably, the Reserves (9,080.00 Cr.) exceed the Borrowings (3,275.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -733.00 | -868.00 | 155.00 | -781.00 | 403.00 | 33.00 | -688.00 | 0.00 | -2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53 | 59 | 78 | 80 | 53 | 36 | 27 | 31 | 36 |
| Inventory Days | 20 | 24 | 26 | 40 | 34 | 24 | 30 | 26 | 26 |
| Days Payable | 184 | 227 | 292 | 273 | 274 | 174 | 215 | 207 | 200 |
| Cash Conversion Cycle | -111 | -144 | -188 | -153 | -187 | -114 | -158 | -149 | -138 |
| Working Capital Days | -12 | -24 | -152 | -191 | -44 | -24 | -46 | -43 | -47 |
| ROCE % | 4% | 6% | 11% | 7% | 12% | 15% | 16% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Equity Hybrid Fund | 7,000,000 | 0.98 | 813.96 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 6,300,000 | 1.74 | 732.56 | N/A | N/A | N/A |
| Kotak Midcap Fund | 5,338,730 | 1.03 | 620.79 | N/A | N/A | N/A |
| Motilal Oswal Midcap Fund | 5,270,000 | 1.61 | 612.8 | N/A | N/A | N/A |
| Invesco India Large & Mid Cap Fund | 4,598,460 | 5.68 | 534.71 | 4,225,932 | 2025-12-14 20:43:52 | 8.82% |
| Canara Robeco Large and Mid Cap Fund | 4,239,096 | 1.88 | 492.92 | N/A | N/A | N/A |
| HDFC Large Cap Fund | 3,798,316 | 1.09 | 441.67 | 2,647,215 | 2025-12-15 06:13:35 | 43.48% |
| PGIM India Midcap Fund | 2,981,264 | 3.01 | 346.66 | 3,526,055 | 2025-12-14 03:33:18 | -15.45% |
| Axis ELSS Tax Saver Fund | 2,447,613 | 0.81 | 284.61 | N/A | N/A | N/A |
| Edelweiss Mid Cap Fund | 2,349,767 | 2.07 | 273.23 | 2,975,393 | 2025-12-14 20:43:52 | -21.03% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 11.07 | 10.89 | 11.38 | 6.25 | -1.59 |
| Diluted EPS (Rs.) | 11.01 | 10.84 | 11.36 | 6.24 | -1.59 |
| Cash EPS (Rs.) | 14.76 | 13.40 | 13.76 | 8.52 | 0.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 96.50 | 86.51 | 76.31 | 64.79 | 58.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 96.50 | 86.51 | 76.31 | 64.79 | 58.37 |
| Revenue From Operations / Share (Rs.) | 72.30 | 55.62 | 46.99 | 40.55 | 25.93 |
| PBDIT / Share (Rs.) | 20.62 | 17.18 | 14.21 | 11.03 | 5.37 |
| PBIT / Share (Rs.) | 16.92 | 14.66 | 11.82 | 8.75 | 3.57 |
| PBT / Share (Rs.) | 14.47 | 14.05 | 10.96 | 7.62 | -0.71 |
| Net Profit / Share (Rs.) | 11.07 | 10.88 | 11.37 | 6.24 | -1.19 |
| NP After MI And SOA / Share (Rs.) | 11.07 | 10.88 | 11.37 | 6.24 | -1.42 |
| PBDIT Margin (%) | 28.51 | 30.89 | 30.24 | 27.21 | 20.70 |
| PBIT Margin (%) | 23.40 | 26.36 | 25.15 | 21.58 | 13.75 |
| PBT Margin (%) | 20.00 | 25.25 | 23.31 | 18.79 | -2.74 |
| Net Profit Margin (%) | 15.30 | 19.56 | 24.18 | 15.38 | -4.57 |
| NP After MI And SOA Margin (%) | 15.30 | 19.56 | 24.18 | 15.38 | -5.49 |
| Return on Networth / Equity (%) | 11.46 | 12.57 | 14.89 | 9.63 | -2.43 |
| Return on Capital Employeed (%) | 12.27 | 13.25 | 12.67 | 10.06 | 4.43 |
| Return On Assets (%) | 7.07 | 8.81 | 10.92 | 6.58 | -1.60 |
| Long Term Debt / Equity (X) | 0.24 | 0.12 | 0.06 | 0.10 | 0.14 |
| Total Debt / Equity (X) | 0.26 | 0.13 | 0.07 | 0.11 | 0.15 |
| Asset Turnover Ratio (%) | 0.51 | 0.48 | 0.21 | 0.21 | 0.18 |
| Current Ratio (X) | 0.87 | 1.37 | 1.86 | 1.32 | 1.45 |
| Quick Ratio (X) | 0.81 | 1.30 | 1.79 | 1.24 | 1.38 |
| Inventory Turnover Ratio (X) | 75.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 13.55 | 9.18 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 10.15 | 7.45 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 86.45 | 90.82 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 89.85 | 92.55 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 12.15 | 27.89 | 16.45 | 10.61 | 2.89 |
| Interest Coverage Ratio (Post Tax) (X) | 7.97 | 18.66 | 14.16 | 7.09 | 1.66 |
| Enterprise Value (Cr.) | 108421.53 | 79785.85 | 41914.32 | 33863.11 | 20147.55 |
| EV / Net Operating Revenue (X) | 15.43 | 14.76 | 9.19 | 8.61 | 8.04 |
| EV / EBITDA (X) | 54.09 | 47.77 | 30.38 | 31.65 | 38.85 |
| MarketCap / Net Operating Revenue (X) | 15.17 | 14.75 | 9.38 | 8.56 | 7.95 |
| Retention Ratios (%) | 86.44 | 90.81 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 11.37 | 9.48 | 5.78 | 5.35 | 3.53 |
| Price / Net Operating Revenue (X) | 15.17 | 14.75 | 9.38 | 8.56 | 7.95 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.01 | -0.01 |
After reviewing the key financial ratios for Max Healthcare Institute Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.89 (Mar 24) to 11.07, marking an increase of 0.18.
- For Diluted EPS (Rs.), as of Mar 25, the value is 11.01. This value is within the healthy range. It has increased from 10.84 (Mar 24) to 11.01, marking an increase of 0.17.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.76. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 14.76, marking an increase of 1.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 96.50. It has increased from 86.51 (Mar 24) to 96.50, marking an increase of 9.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 96.50. It has increased from 86.51 (Mar 24) to 96.50, marking an increase of 9.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 72.30. It has increased from 55.62 (Mar 24) to 72.30, marking an increase of 16.68.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.62. This value is within the healthy range. It has increased from 17.18 (Mar 24) to 20.62, marking an increase of 3.44.
- For PBIT / Share (Rs.), as of Mar 25, the value is 16.92. This value is within the healthy range. It has increased from 14.66 (Mar 24) to 16.92, marking an increase of 2.26.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 14.05 (Mar 24) to 14.47, marking an increase of 0.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.88 (Mar 24) to 11.07, marking an increase of 0.19.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 10.88 (Mar 24) to 11.07, marking an increase of 0.19.
- For PBDIT Margin (%), as of Mar 25, the value is 28.51. This value is within the healthy range. It has decreased from 30.89 (Mar 24) to 28.51, marking a decrease of 2.38.
- For PBIT Margin (%), as of Mar 25, the value is 23.40. This value exceeds the healthy maximum of 20. It has decreased from 26.36 (Mar 24) to 23.40, marking a decrease of 2.96.
- For PBT Margin (%), as of Mar 25, the value is 20.00. This value is within the healthy range. It has decreased from 25.25 (Mar 24) to 20.00, marking a decrease of 5.25.
- For Net Profit Margin (%), as of Mar 25, the value is 15.30. This value exceeds the healthy maximum of 10. It has decreased from 19.56 (Mar 24) to 15.30, marking a decrease of 4.26.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.30. This value is within the healthy range. It has decreased from 19.56 (Mar 24) to 15.30, marking a decrease of 4.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.46. This value is below the healthy minimum of 15. It has decreased from 12.57 (Mar 24) to 11.46, marking a decrease of 1.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.27. This value is within the healthy range. It has decreased from 13.25 (Mar 24) to 12.27, marking a decrease of 0.98.
- For Return On Assets (%), as of Mar 25, the value is 7.07. This value is within the healthy range. It has decreased from 8.81 (Mar 24) to 7.07, marking a decrease of 1.74.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has increased from 0.12 (Mar 24) to 0.24, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.26. This value is within the healthy range. It has increased from 0.13 (Mar 24) to 0.26, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has increased from 0.48 (Mar 24) to 0.51, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 0.87. This value is below the healthy minimum of 1.5. It has decreased from 1.37 (Mar 24) to 0.87, marking a decrease of 0.50.
- For Quick Ratio (X), as of Mar 25, the value is 0.81. This value is below the healthy minimum of 1. It has decreased from 1.30 (Mar 24) to 0.81, marking a decrease of 0.49.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 75.55. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 75.55, marking an increase of 75.55.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.55. This value is below the healthy minimum of 20. It has increased from 9.18 (Mar 24) to 13.55, marking an increase of 4.37.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 10.15. This value is below the healthy minimum of 20. It has increased from 7.45 (Mar 24) to 10.15, marking an increase of 2.70.
- For Earning Retention Ratio (%), as of Mar 25, the value is 86.45. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 24) to 86.45, marking a decrease of 4.37.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 89.85. This value exceeds the healthy maximum of 70. It has decreased from 92.55 (Mar 24) to 89.85, marking a decrease of 2.70.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 12.15. This value is within the healthy range. It has decreased from 27.89 (Mar 24) to 12.15, marking a decrease of 15.74.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.97. This value is within the healthy range. It has decreased from 18.66 (Mar 24) to 7.97, marking a decrease of 10.69.
- For Enterprise Value (Cr.), as of Mar 25, the value is 108,421.53. It has increased from 79,785.85 (Mar 24) to 108,421.53, marking an increase of 28,635.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 15.43. This value exceeds the healthy maximum of 3. It has increased from 14.76 (Mar 24) to 15.43, marking an increase of 0.67.
- For EV / EBITDA (X), as of Mar 25, the value is 54.09. This value exceeds the healthy maximum of 15. It has increased from 47.77 (Mar 24) to 54.09, marking an increase of 6.32.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 15.17. This value exceeds the healthy maximum of 3. It has increased from 14.75 (Mar 24) to 15.17, marking an increase of 0.42.
- For Retention Ratios (%), as of Mar 25, the value is 86.44. This value exceeds the healthy maximum of 70. It has decreased from 90.81 (Mar 24) to 86.44, marking a decrease of 4.37.
- For Price / BV (X), as of Mar 25, the value is 11.37. This value exceeds the healthy maximum of 3. It has increased from 9.48 (Mar 24) to 11.37, marking an increase of 1.89.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 15.17. This value exceeds the healthy maximum of 3. It has increased from 14.75 (Mar 24) to 15.17, marking an increase of 0.42.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Max Healthcare Institute Ltd:
- Net Profit Margin: 15.3%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.27% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.46% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 72.6 (Industry average Stock P/E: 92.93)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 15.3%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 401, 4th Floor, Man Excellenza, Mumbai Maharashtra 400056 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Abhay Soi | Chairman & Managing Director |
| Mr. Pranav Amin | Independent Director |
| Mr. Michael Thomas Neeb | Independent Director |
| Mr. K Narasimha Murthy | Independent Director |
| Mr. Anil Kumar Bhatnagar | Non Executive Director |
| Mr. Narayan K Seshadri | Non Executive Director |
| Ms. Amrita Gangotra | Independent Woman Director |
| Mr. Mahendra Gumanmalji Lodha | Independent Director |
| Dr. Pranav C Mehta | Independent Director |
FAQ
What is the intrinsic value of Max Healthcare Institute Ltd?
Max Healthcare Institute Ltd's intrinsic value (as of 06 January 2026) is ₹760.81 which is 27.68% lower the current market price of ₹1,052.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,02,370 Cr. market cap, FY2025-2026 high/low of ₹1,314/940, reserves of ₹9,080 Cr, and liabilities of ₹16,281 Cr.
What is the Market Cap of Max Healthcare Institute Ltd?
The Market Cap of Max Healthcare Institute Ltd is 1,02,370 Cr..
What is the current Stock Price of Max Healthcare Institute Ltd as on 06 January 2026?
The current stock price of Max Healthcare Institute Ltd as on 06 January 2026 is ₹1,052.
What is the High / Low of Max Healthcare Institute Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Max Healthcare Institute Ltd stocks is ₹1,314/940.
What is the Stock P/E of Max Healthcare Institute Ltd?
The Stock P/E of Max Healthcare Institute Ltd is 72.6.
What is the Book Value of Max Healthcare Institute Ltd?
The Book Value of Max Healthcare Institute Ltd is 103.
What is the Dividend Yield of Max Healthcare Institute Ltd?
The Dividend Yield of Max Healthcare Institute Ltd is 0.14 %.
What is the ROCE of Max Healthcare Institute Ltd?
The ROCE of Max Healthcare Institute Ltd is 14.9 %.
What is the ROE of Max Healthcare Institute Ltd?
The ROE of Max Healthcare Institute Ltd is 12.7 %.
What is the Face Value of Max Healthcare Institute Ltd?
The Face Value of Max Healthcare Institute Ltd is 10.0.